Telmisartan and Rosuvastatin Synergistically Ameliorate Dementia and Cognitive Impairment in Older Hypertensive Patients With Apolipoprotein E Genotype

Wenjing Hu, Ying Li, Yingxin Zhao, Yuanli Dong, Yi Cui, Shangwen Sun, Gary Gong, Hua Zhang, Qiang Chai, Juan Wang, Zhendong Liu

Research output: Contribution to journalArticlepeer-review

1 Scopus citations


Objective: To investigate the effect of telmisartan, rosuvastatin, or their combination on dementia and to understand the impact of apolipoprotein E (APOE) genotype on the effect of the medications in older patients with hypertension. Methods: This is a double-blind, randomized, and placebo-controlled trial using a 2 × 2 factorial design. Between April 2008 and November 2010, 1,244 hypertensive patients aged ≥60 years without cognitive impairment were recruited from communities in six cities in Shandong area, China. Patients were randomized into telmisartan and rosuvastatin administration after a 2-week washout period. APOE genotype was identified at the baseline. Possible dementia was determined using the combination of the global cognitive function and Assessment of the Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE). Results: Over an average follow-up of 7 [interquartile range (IQR): 6.7–7.2] years, telmisartan and rosuvastatin significantly reduced the cognitive impairment progression and the incidence of dementia. There was a synergistic interaction between telmisartan and rosuvastatin to reduce the cognitive impairment and the incidence of dementia (Padjusted < 0.001). The cognitive impairment progression and the risk of dementia were higher in the hypertensive patients with APOE ε4 allele than in those without APOE ε4 allele. Rosuvastatin medication significantly alleviated the cognitive impairment progression and the risks of dementia in patients with APOE ε4 allele. Conclusion: The combination of telmisartan and rosuvastatin might be an effective prevention and/or treatment strategy for cognitive impairment and dementia, especially in hypertensive patients with the APOE ε4 allele. Clinical Trial Registration:,, identifier ChiCTR-IOR-17013557. Registered on April 12, 2017 – Retrospectively registered,

Original languageEnglish (US)
Article number154
JournalFrontiers in Aging Neuroscience
StatePublished - Jun 9 2020


  • anti-hypertension
  • apolipoprotein E
  • cognitive impairment
  • dementia
  • hypertension
  • lipid lowering

ASJC Scopus subject areas

  • Aging
  • Cognitive Neuroscience


Dive into the research topics of 'Telmisartan and Rosuvastatin Synergistically Ameliorate Dementia and Cognitive Impairment in Older Hypertensive Patients With Apolipoprotein E Genotype'. Together they form a unique fingerprint.

Cite this